Categories
Blood Cancer

BELINDA: Tisagenlecleucel in B-cell NHL [Video]

Michael Bishop, MD, University of Chicago, Chicago, IL, discusses results from the Phase III BELINDA trial (NCT03570892), which assessed tisagenlecleucel (tisa-cel), a chimeric antigen receptor (CAR) T-cell therapy, in patients with aggressive B-cell non-Hodgkin lymphoma. The primary endpoint, which was event-free survival, was not met, and tisa-cel was not superior to the current standard of care. Dr Bishop highlights the time taken for the therapy to be administered, bridging therapy, and the dosage of lymphodepleting chemotherapy to be factors affecting the trial results. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

CAR-T therapy in multiple myeloma: research blind spots [Video]

CAR T-cell therapy has been shown to elicit high-quality responses in patients with multiple myeloma. Positive data from the pivotal Phase II KarMMa trial led to the approval of idecabtagene vicleucel, a BCMA-directed CAR T-cell therapy, in patients with heavily pretreated relapsed/refractory myeloma, and ongoing trials are investigating the utility of CAR-T versus standard of care regimens in earlier lines of treatment. Andrew Cowan, MD, University of Washington, Seattle, WA, discusses the blind spots in myeloma CAR-T research, highlighting key topics such as treatment sequencing, combination studies, and retreatment with BCMA-targeted therapies. This interview took place at during 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

The role of immunotherapy in multiple myeloma [Video]

Nina Shah, MD, University of California, San Francisco, CA, provides her insights on the future of multiple myeloma treatment. Multiple advancements have been made in recent years, especially with the development of immunotherapies. In addition to existing monoclonal antibodies such as daratumumab and isatuximab, chimeric antigen receptor (CAR) T-cell therapies including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) represent alternative therapies for patients with relapsed/refractory multiple myeloma. Dr Shah additionally highlights the development of bispecific T-cell engagers (BiTEs), as well moving immunotherapies into the frontline setting. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

The role of CAR-T therapy in hematologic malignancies [Video]

Michael Bishop, MD, University of Chicago, Chicago, IL, describes advances in chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. Data from the JULIET (NCT02445248), TRANSFORM (NCT03575351), BELINDA (NCT03570892), ZUMA-1 (NCT02348216), and ZUMA-7 (NCT03391466) trials have demonstrated CAR T-cell therapy as a promising frontline therapy in non-Hodgkin lymphoma. Dr Bishop additionally highlights updates in multiple myeloma and acute lymphoblastic leukemia (ALL), as well as strategies to manage CAR T-cell toxicity. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Novel immunotherapy combinations in Hodgkin lymphoma [Video]

Sanjal Desai, MBBS, Mayo Clinic, Rochester, MN, discusses novel immunotherapy approaches currently being evaluated in Hodgkin lymphoma. Pembrolizumab in combination with gemcitabine-based chemotherapy or the ifosfamide, carboplatin, etoposide (ICE) regimen is a promising salvage therapy, and pembrolizumab with doxorubicin, vinblastine, and dacarbazine (AVD) is another potential regimen for frontline therapy. Nivolumab and ruxolitinib is an additional combination that may sensitize patients with relapsed/refractory Hodgkin lymphoma to immunotherapy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

The future of lymphoma therapies [Video]

Mahmoud Elsawy, MB BCh, MSc, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, discusses the latest advancements in the field of lymphoma research and treatment. He highlights the development of immunotherapies including chimeric antigen receptor (CAR) T-cell therapy, which will enable more durable responses. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Advancements in the field of Hodgkin lymphoma [Video]

Sanjal Desai, MBBS, Mayo Clinic, Rochester, MN, describes future developments in the Hodgkin lymphoma treatment landscape. Immunotherapy is playing an increasingly important role within Hodgkin lymphoma treatment. Brentuximab vedotin has demonstrated superior progression-free survival compared to conventional chemotherapies such as gemcitabine. Monoclonal antibodies including nivolumab and pembrolizumab are being recommended as combination therapies with chemotherapy or first-line therapy for treatment-naïve patients and Dr Desai additionally highlights the need for further treatment options for patients who progress on immunotherapy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Molecules versus cells for Hodgkin lymphoma management [Video]

Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, discusses the use of immunological molecules versus cellular therapy in the management of Hodgkin Lymphoma. A plethora of data is emerging that demonstrates the potential of numerous agents, including CAR T-cells, bispecific antibodies, and other immunologically active agents. Prof. Ansell comments that currently, one category has not shown to be superior than the other, with exciting data coming out to support the use of both. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Will CAR-T therapy take over from autologous transplantation in lymphoma? [Video]

Is there still a role for autologous stem cell transplantation in lymphoma? Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, shares his thoughts on this pertinent subject. With the emergence of highly active novel therapies, the use of autologous transplantation has come into question. Several studies have directly compared the use of CAR-T therapy versus transplantation, with mixed results. Further investigations are needed to determine if there are select populations who may benefit more from one approach or the other. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

ZUMA-7: Axi-cel in r/r large B-cell lymphoma [Video]

Frederick Locke, MD, Moffitt Cancer Center, Tampa, FL, presents results from the Phase III ZUMA-7 trial (NCT03391466) which assessed axicabtagene ciloleucel (axi-cel), an autologous anti‑CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL). 359 patients either received axi-cel or the standard of care, with the primary endpoint being event-free survival (EFS). After a 24 month follow-up, patients in the axi-cel arm demonstrated a superior EFS and overall response rate (ORR). Overall survival (OS) was additionally superior in the axi-cel arm, but was not statistically significant. The results suggest axi-cel can be a second-line treatment for r/r LBCL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Developing off-the-shelf CAR T-cells to treat multiple myeloma [Video]

Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, shares an update on the latest developments regarding off-the-shelf CAR T-cell therapeutics for the treatment of multiple myeloma, commenting on toxicity issues that have recently emerged. Data from the Phase I UNIVERSAL trial (NCT04093596) of an anti-BCMA allogeneic CAR-T product will be presented at the ASH 2021 annual meeting. Several other trials are ongoing. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Looking forward to ASH 2021: key updates in DLBCL [Video]

Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, gives an overview of the main updates in diffuse large B-cell lymphoma (DLBCL) that will be discussed at the upcoming ASH annual meeting. To begin with, the data from the POLARIX trial comparing the efficacy of polatuzumab vedotin plus R-CHP versus R-CHOP in previously untreated DLBCL (NCT03274492) is eagerly awaited, as a recent press release reported that the primary endpoint was met. In addition, updates from the ZUMA-7 study investigating the efficacy of axicabtagene ciloleucel versus standard of care (SOC) in relapsed/refractory DLBCL (NCT03391466) will be presented at ASH, as well as new exciting data on bispecific antibodies for lymphoma. Dr Collins is also looking forward to hearing more details about the real-world data from a study evaluating the outcomes of different central nervous system (CNS) prophylaxis strategies in DLBCL which could have a substantial impact on clinical practice. Finally, an interesting study investigating the use of cell-free DNA (cfDNA) as a diagnostic and prognostic biomarker in primary CNS lymphoma will be presented at the Plenary Scientific Session. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.